

PATENT APPLICATION
Atty. Docket No. PP019813.0003RECEIVED
CENTRAL FAX CENTER

REMARKS

MAY 24 2007

The Examiner has required restriction between Group I (claims 1-9 and 11 with SEQ ID 2), Group II (claims 1-9 and 11 with SEQ ID 3), Group III (claims 1-9 and 11 with SEQ ID 4), Groups IV-VI (Claim 10, wherein group IV corresponds to Group I mutant protein..and Group XII corresponds to Group III mutant protein), Groups VII-IX (Claim 12, wherein Group XIII corresponds to antibody that binds to Group I mutant protein...and Group XV corresponds to antibody that binds to Group III mutant protein), Groups X-XII (Claim 13, wherein Group XVI corresponds to nucleic acid encoding Group I mutant protein...and Group XVIII corresponds to nucleic acid encoding Group III mutant protein, Groups XIII-XXI (Claim 14...), Group XXII (Claim 15). By way of the amendment, Applicants have elected Group III, claims 1-9 and 11 with SEQ ID NO 4 for continued examination, without traverse for prosecution.

Cancellation and amendment of the claims is made without prejudice, without intent to abandon any originally claimed subject matter, and without intent to acquiesce in any rejection of record. Applicants expressly reserve the right to file one or more continuing applications hereof containing the cancelled or unamended claims.

Since the application provides support for each of the above amendments, entry of these amendments is respectfully requested. The amendments do not introduce new matter.

If further fees are required, the Commissioner is authorized to charge any deficiencies to deposit account 03-1664. However, this is not authorization to charge the Issue Fee.

Respectfully submitted,

By: 

Amy L. Hessler

Registration No. 50,310

May 24, 2007
DateCustomer No. 27476

Amy L. Hessler

Novartis Vaccines and Diagnostics, Inc.

Corporate Intellectual Property

P.O. Box 8097

Emeryville, CA 94662-8097

Telephone: (510) 923-3833

Facsimile: (510) 655-3542